NCT01259986

Brief Summary

The purpose of this study is the evaluate the efficacy of using a low-energy 635 nm visible light laser in the treatment of various recalcitrant forms of vitiligo.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2010

Typical duration for not_applicable

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2010

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 14, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 15, 2010

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2011

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2012

Completed
Last Updated

September 27, 2012

Status Verified

September 1, 2012

Enrollment Period

8 months

First QC Date

December 14, 2010

Last Update Submit

September 26, 2012

Conditions

Keywords

VitiligoLaserSegmental vitiligoAcral vitiligo

Outcome Measures

Primary Outcomes (1)

  • Percent repigmentation

    24 clinic visits over 12 weeks

Study Arms (1)

Laser treatment

EXPERIMENTAL
Procedure: Laser treatment

Interventions

Laser treatment of using 635 nm laser with a dose of 3.0 J/cm\^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.

Laser treatment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Be at least 18 years old
  • Have active or stable segmental vitiligo on the neck or face, acral vitiligo, or have undergone recent melanocyte-keratinocyte transplantation procedure (MKTP)
  • Agree to abide by the Investigator's guidelines regarding photosensitizing drugs and photoprotection
  • Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form
  • Agree to follow and undergo all study-related procedures

You may not qualify if:

  • Women who are lactating, pregnant, or planning to become pregnant
  • Patients with a recent history of melasma, and other disorders of pigmentation with the exception of post inflammatory hyperpigmentation
  • Patients with a known history of photosensitivity disorders
  • Photosensitizing medications may be continued throughout of the study at the discretion of the investigator
  • Patients with a known history of melanoma or non-melanoma skin cancers
  • Concomitant use of tanning beds
  • Any reason the investigator feels the patient should not participate in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Vitiligo

Interventions

Laser Therapy

Condition Hierarchy (Ancestors)

HypopigmentationPigmentation DisordersSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

TherapeuticsAblation TechniquesSurgical Procedures, Operative

Study Officials

  • Iltefat H. Hamzavi, M.D.

    Henry Ford Health System

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dermatologist

Study Record Dates

First Submitted

December 14, 2010

First Posted

December 15, 2010

Study Start

October 1, 2010

Primary Completion

June 1, 2011

Study Completion

September 1, 2012

Last Updated

September 27, 2012

Record last verified: 2012-09